Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot154010.32687/0869-866X-2024-32-5-933-940НеопределенThe development of regulation of pharmaceuticals turn-over in EU and the USA in 1992–2020. Report 3. The making of the EU legislation of pharmaceuticals turn-over in 2001–2020VolskayaE Avols-elena@yandex.ruN. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia271020243252604202526042025Copyright © 2025,2025<p>This article proceeds the topic of the article The development of regulation of the circulation of medicines in the EU and the USA in 19922020. The history of development of European pharmaceutical legislation in 20012020 is considered. The acts of indirect action adopted by EU Parliament at first stage of development of legislation concerning medications failed to fully harmonize normative base of the EU Member States in pharmaceutical market. Since 2000, the EU Parliament and the EU Council adopt laws of direct action the Regulations. Alongside with the pharmaceutical Code, the Regulations for single segments of pharmaceutical market constituted set of laws related to turn-over of medications. The legislators, at developing EU laws, took into account the US regulatory standards. Despite differences in history, legislative traditions and structure, regulatory systems of the USA and the EU concerning medications turn-over were basically harmonized.</p>medicationspharmaceutical legislationharmonizationregulationdirectiveлекарственные средствафармацевтическое законодательствогармонизациярегулирование деятельностидирективарегламент[Volkov A. K., Ryzhkov A. A Impact of European Union law on regulation of national pharmaceutical markets of Member States. Law. Journal HSE. 2013;(2):116–33 (in Russian).][Bunjatjan N. D., Sakaeva I. V., Kosareva T. V., Korsun L. V., Sakanjan V. A. Comparative Characteristics of the Drug Registration System in the Russian Federation and European Union Countries. Sheetsof the Scientific Center for Expertise of Medical Products. Regulatory studies and expertise of medicinal products. 2011;(2):39–42 (in Russian).][Krichevskaja E. F. State regulation of the pharmaceutical market in the countries of the European Union. Economics and Law. 2020;(11):42–6 (in Russian).][Olefir Ju. V., Digtjar' A. V., Rychihina E. M. Prerequisites and objectives for establishing the orphan status of the medicinal product. World experience and requirements of the legislation of the Russian Federation. Analytical review. International Journal of Applied and Basic Research. 2016;(6-2):335–53 (in Russian).][Lezotre P.-L. Recommendations to Support the Next Phase of International Cooperation, Convergence, and Harmonization. The Pharmaceutical Domain in International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations, 2014. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/pharmaceuticals-regulation][General principles of medicines regulation. In Adrian Kilcoyne (ed.). Pharmaceutical Medicine. Oxford University Press; 2013. P. 19–21. Available at: https://doi.org/10.1093/med/9780199609147. 003.0006][Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32000R0141][Volskaya E. “Orphan drugs” — Chance for Russian manufacturers? Remedium. 2002;(6):30–2 (in Russian).][Giannuzzi V., Conte R., Landi A., et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Disease.2017;12 (1):64. Available at: https://ojrd.biomedcentral.com/][Michaux G. EU Orphan Regulation — Ten Years of Application. Food Drug Law J. 2010;65(4):639–69.][Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A32004R0273][Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Available at: https://eur-lex.europa.eu/eli/reg/2004/726/oj][Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32006R1901][Kurz R. Ethik in der paediatrischen Forschung. Monatsschrift Kinderheilkunde. 2003;12:1276–81.][Kinder sind keine kleinen Erwachsenen. 15/2009, 06.07.2009. Available at: https://www.bfr.bund.de/de/presseinformation/2009/15/kinder_sind_keine_kleinen_erwachsenen-30129.html#top][An act to amend the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require certain research into drugs used in pediatric patients. Available at: https://www.govinfo.gov/app/details/PLAW-108publ155][Schuch Т. EU gegen Off-Label-Einsatz. Medical Tribune. 2010; 42:24.][Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance). Available at: https://eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:32007R1394][Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex% 3A32014R0536][Explanatory Memorandum to COM(2012)369 — Clinical trials on medicinal products for human use. Available at: https://www.eumonitor.eu/9353000/1/j4nvhdfdk3hydzq_j9vvik7m1c3gyxp/vj19rqf41bwf][Volskaya E. Modernization of clinical research management in the European Union. Remedium. 2015;(4):6–9 (in Russian).][History of the EU. Available at: https://european-union.europa.eu/principles-countries-history/history-eu_en]